Is Viatris a Millionaire-Maker Stock?
You may have been taken by surprise earlier this month when a new pharmaceutical stock landed in your portfolio that you didn't know you bought -- Viatris (NASDAQ: VTRS).
It may seem like a new stock, but it isn't really. Viatris, which was formed of the combination of Mylan and the Upjohn division of Pfizer, started trading on the Nasdaq on Nov. 17. You're probably already familiar with many of Viatris' therapies such as Xanax, Lipitor, Celebrex, Viagra, and Zoloft, which were originally part of Upjohn's stable of branded drugs. They account for 60% of the new company's expected revenue with the rest coming from its generic products, most of which have come from Mylan.
Could Viatris be a millionaire-maker stock? To figure that out, we must determine if it has enough growth potential and stability to justify a large investment.
Source Fool.com
